As revealed by Fig. 7A, co-treatment of chemotherapeutics such as gemcitabine, decitabine, etoposide, cytarabine, as well as targeted therapies including gilteritinib (FLT3), sorafenib (broad-spectrum tyrosine kinase inhibitor) showed minor synergetic inhibitory effects compared with monotherapy in a panel of hematological cancer cell lines. The gene discussed is FLT3; the disease is hematopoietic and lymphoid cell neoplasm.